IOL Chemicals Reports 9.8% Revenue Growth and 19.5% EBITDA Jump in Q1 Aug 13, 2025
IOL Chemicals Unveils Strategic Expansion Plan Amid Strong Q1 Performance Aug 07, 2025
More news about IOL Chemicals & Pharmaceuticals
07Aug 25
IOL Chemicals and Pharmaceuticals Reports Strong Q1 Performance, Plans UK Subsidiary and Minoxidil Production
IOL Chemicals & Pharmaceuticals announced strong Q1 results with a 9.8% revenue increase to ₹551.69 crore and a 14.5% rise in net profit to ₹34.00 crore. The company's EBITDA grew to ₹62.10 crore with an improved margin of 11.3%. The pharmaceutical segment led revenue generation at ₹329.33 crore. The Board approved establishing a wholly-owned subsidiary in the UK and plans to manufacture Minoxidil with a 120 MTPA capacity at a new Unit 9B, investing ₹5.50 crore from internal funds. The project is set for completion by December 2025.
13Jun 25
IOL Chemicals Secures EU REACH Registration for Acetic Anhydride
IOL Chemicals & Pharmaceuticals has successfully registered Acetic Anhydride under the European Union's REACH regulation. This achievement allows the company to export the product to all EU member states, potentially enhancing its global presence and opening new revenue streams in the European market. The registration demonstrates IOL's compliance with international regulatory standards and its commitment to expanding its global footprint.
16May 25
IOL Chemicals: Q4 Net Profit Rises 13.7%, Margins Expand
IOL Chemicals and Pharmaceuticals Ltd announced impressive Q4 financial results. EBITDA increased by 28.5% to ₹62.60 crore, with EBITDA margin improving to 11.80%. Net profit rose by 13.7% to ₹31.42 crore, while revenue grew by 4.7% to ₹527.70 crore. The company demonstrated improved operational efficiency and effective cost management.
24Mar 25
IOL Chemicals and Pharma Boosts Production Capacity with New Paracetamol Unit and Clopidogrel Expansion
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has significantly expanded its production capabilities. The company launched a new Paracetamol production unit with a capacity of 10,800 MTPA, increasing total capacity to 14,400 MTPA. IOLCP also expanded its Clopidogrel Bisulphate manufacturing capacity from 180 MTPA to 240 MTPA. The Paracetamol expansion cost Rs 155.51 crore, while the Clopidogrel expansion required Rs 7.87 crore, both funded through internal accruals. The new Paracetamol unit includes backward integration with in-house production of key intermediates.